ABSTRACT OBJECTIVES This study sought to investigate the prognostic importance of a low diffusion capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
HFpEF has become a leading cause of congestive heart failure that predominantly affects elderly patients (5, 6) . Risk factors include age, hypertension, coronary heart disease, obesity, and diabetes (5).
At least 50% of patients with HFpEF develop pulmonary hypertension (PH) (2, 7, 8) , which presents either as isolated post-capillary PH or as postcapillary PH with a pre-capillary component (9, 10) .
The development of PH in patients with HFpEF (PH-HFpEF) is associated with increased mortality
The pathogenesis of PH in patients with
HFpEF is incompletely understood. It is selfevident that a rise in left-sided filling pressures and the pulmonary venous system translates directly into elevated pulmonary arterial pressures, in other words, isolated post-capillary PH. What is unclear is why some patients develop a significant pre-capillary component, as indicated by a diastolic pressure gradient >7 mm Hg and a pulmonary vascular resistance (PVR) >240 dyn$s$cm -5 (11) . It has been hypothesized that these patients may develop an angioproliferative pulmonary vasculopathy similar to what is seen in patients with pulmonary arterial hypertension (9) . Histological confirmation of this hypothesis, however, is lacking.
The diffusion capacity of the lung for carbon monoxide (DLCO) is increasingly recognized as an important diagnostic and prognostic variable in patients with pulmonary vascular disease (12) . In idiopathic pulmonary arterial hypertension (IPAH), DLCO is usually normal or moderately impaired (13, 14) , but a subgroup of these patients presents with a low DLCO (<45% of the predicted value), and these patients have a particularly high mortality (15) .
Similar findings have been reported in patients with chronic lung disease and PH (16) (17) (18) .
Little is known about the role of DLCO in patients with PH-HFpEF. In a recent study assessing predictors of mortality in these patients, a DLCO <35% of the predicted value was associated with increased mortality, whereas a DLCO $65% of the predicted value was associated with a survival benefit (19) . Other than that, there are sparse data on the role of DLCO measurements in this patient population. The present study was conducted to further evaluate the distribution of DLCO measurements in patients with PH-HFpEF, factors associated with a low DLCO, and the prognostic importance of a low DLCO in this patient population. predicted and a forced expiratory capacity in 1 s $60% predicted; and 4) exclusion of chronic thromboembolic pulmonary hypertension by ventilation/perfusion scintigraphy, and pulmonary angiography, if necessary. All assessments were done in stable and compensated patients who presented without clinically overt heart failure.
All patients provided written informed consent, and the study was approved by the local ethics committee.
RIGHT HEART CATHETERIZATION. All patients underwent right heart catheterization with determination of right atrial pressure; systolic, diastolic, and mean pulmonary artery pressure; and pulmonary arterial wedge pressure because of suspected severe PH. Cardiac output was determined by thermodilution. PVR, cardiac index, and diastolic pressure gradient were calculated by standard formula. Mixed venous oxygen saturation was determined from pulmonary artery blood samples. The date of PH-HFpEF diagnosis was defined as the date of the first right heart catheterization showing PH.
PULMONARY FUNCTION TESTS, DLCO MEASUREMENTS
AND SMOKING STATUS. Spirometry and body plethysmography were used to determine total lung capacity, forced vital capacity, forced expiratory capacity in 1 s, and the ratio between residual volume and total lung capacity (20) . DLCO was measured by the single- BLOOD GASES AND LABORATORY ANALYSIS. Experienced technicians obtained arterialized capillary blood gases from earlobes after a resting period $10 min while patients were breathing room air (22) . The blood samples were analyzed without delay using a standard device (Radiometer, Copenhagen, Denmark).
Routine laboratory assessments were done in all patients at the time of right heart catheterization. Patients in the DLCO <45% group were more often male and on average 3 years older than patients in the DLCO $45% group (Table 1) . They had a slightly lower JACC: HEART FAILURE VOL. 4, NO. 6, 2016
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DLCO in PH-HFpEF body mass index, a higher incidence of coronary heart disease, and a nonsignificant trend toward a higher incidence of diabetes. Lung function parameters were almost identical in the 2 groups, whereas blood gas analysis showed more severely impaired oxygenation in the DLCO <45% group. Hemodynamics and laboratory variables including NT-proBNP levels did not differ between the 2 cohorts. Patients in the DLCO <45% group had a more frequent smoking history and a higher number of pack years ( Table 1) .
ROC ANALYSIS. According to receiver-operating characteristic analysis, DLCO at 45% of the COMPUTED TOMOGRAPHY SCANS. In total, we were able to retrieve CT scans or CT reports, respectively, from 64 patients (59%) including 31 patients (60%) with a low DLCO. CT images for on-site review were available from 22 patients (20%), including 8 with a low DLCO. In the majority of CT scans (43 of 64, 67%), no lung parenchymal abnormalities were seen or reported.
In the DLCO #45% group, 17 (55%) of the 31 CT scans showed no parenchymal abnormalities. In the remaining 14 CT scans, emphysematous changes were reported in 6 patients, fibrotic changes in 4 patients, and combined fibrotic and emphysematous changes in 4 patients. Of these, 6 were rated as mild, 7 as moderate, and 1 as severe. Thirty-three CT scans were available from the DLCO >45% group; 26 (79%) were described as normal. Parenchymal abnormalities were noted in 7 patients (21%) in the DLCO >45% group (emphysematous changes, n ¼ 4; fibrotic changes, n ¼ 3), of which 5 were rated as mild, 1 as moderate, and 1 as severe. ACE ¼ angiotensin-converting enzyme; CO ¼ cardiac output; DLCO ¼ diffusion capacity for carbon monoxide; E/e 0 ¼ mitral flow velocity (E)/myocardial diastolic motion (e 0 ); FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; GFR ¼ glomerular filtration rate; LA ¼ left atrium; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PaCO2 ¼ partial arterial pressure of carbon dioxide; PaO2 ¼ partial arterial pressure of oxygen; PAPdiast ¼ diastolic pulmonary arterial pressure; PAPm ¼ mean pulmonary arterial pressure; PAPsyst ¼ systolic pulmonary arterial pressure; PAWP ¼ pulmonary artery wedge pressure; PH-HFpEF ¼ pulmonary hypertension due to heart failure with preserved ejection fraction; % pred ¼ % predicted; PVR ¼ pulmonary vascular resistance; RV ¼ residual volume; RVEDD ¼ right ventricular end-diastolic diameter; SaO2 ¼ saturation of oxygen; SvO2 ¼ mixed venous oxygen saturation; SVR ¼ systemic vascular resistance; TAPSE ¼ tricuspid plane annular systolic excursion; TLC ¼ total lung capacity.
FIGURE 1 DLCO Distribution in the Present Patient Population
Histogram shows the diffusion capacity for carbon monoxide (DLCO) in our cohort.
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Hoeper et al. Overall, 44 patients (40.7%) died during the observation period, 32 (62%) in the DLCO <45% group, and 12 (21%) in the DLCO $45% group (p < 0.001). The survival rates in the whole patient cohort were 93.5%, 74.1%, 64.1%, and 45.5% at 1, 2, 3, and 5 years, respectively. In the DLCO $45% group, the survival rates at 1, 2, 3, and 5 years were 98.2%, 96%, 87.8%, and 68.2%. In the DLCO <45% group, the respective survival rates were 88.3%, 49.3%, 36.5%, and 17.1%. The difference between both groups was highly statistically significant (p < 0.001 by log-rank analysis) (Figure 3) .
COX REGRESSION ANALYSIS. We performed 2 Cox regression analyses. In the first model ( Table 2) In the second Cox regression model (Table 3) , DLCO was categorized into the 2 pre-defined DLCO groups-DLCO <45% and DLCO $45% . In the univariate model, DLCO <45% , NT-proBNP, smoking history, and pack years were associated with an increased mortality risk, but only DLCO <45% remained a significant predictor of death in the multivariate model. In this model, the C-index was 0.5 without DLCO and 0.729 when DLCO was included.
In both models, age, sex, New York Heart Association functional class, 6-min walk distance, smoking history, hemodynamic parameters, and pulmonary function test variables other than DLCO did not predict outcome in this patient population, either in the univariate or in the multivariate analysis. Bilirubin, glomerular filtration rate, and mixed venous oxygen saturation were not included in the Cox regression models because more than 30% of the data were missing.
DISCUSSION
The present study showed a wide DLCO distribution among patients with PH-HFpEF. A DLCO below 45% of the predicted value was found in almost one-half of the patients, predominantly in male smokers. Of note, the low DLCO was seen in patients with otherwise normal pulmonary function, the majority of whom also had normal chest CT findings. There was no association between the DLCO and the severity of PH, but a low DLCO was strongly and independently associated with the risk of death. The 3-year mortality in patients with a DLCO <45% was almost 3Â higher Kaplan-Meier analysis shows the survival estimates of the whole group, of patients with a DLCO below 45% (DLCO <45% ) of the predicted values, and of patients with a DLCO equal to or above 45% (DLCO $45% ) of the predicted value. DLCO ¼ diffusion capacity for carbon monoxide. Numbers at risk after 1, 2, 3, 4, and 5 years were 44, 16, 8, 5 , and 1, respectively , in the DLCO<45 % group, and 55, 52, 31, 22, and 12, respectively in the DLCO $45% group. The DLCO is determined by the alveolar capillary volume and a membrane diffusion component (13) .
A low DLCO in patients with pre-capillary PH has been linked to a reduced alveolar capillary volume (24) . In patients with PH-HFpEF, chronic interstitial edema impairing membrane diffusion could be a potential cause of a low DLCO as it has been reported in patients with HF with reduced EF (25-27).
Melenovsky et al. (28) recently showed that lung fluid overload as determined by pulmonary radiography was associated with a lower DLCO, a higher PVR, and right ventricular dilation (28) . However, it is unlikely that interstitial edema contributed substantially to the low DLCO in our patients as we included only patients who presented in a stable, compensated state. In addition, no signs of pulmonary venous congestion were reported on the chest CT scans, and hemodynamics including left ventricular filling pressures were identical in both DLCO groups.
The DLCO tends to be normal or mildly to moderately reduced in the majority of patients with IPAH and chronic thromboembolic PH (13) (14) (15) 29) . In both conditions, the vascular lesions are found predominantly in the pre-capillary vessels, and there is usually little capillary or post-capillary involvement (30) , which may explain why DLCO is generally not substantially affected by these conditions. Pulmonary vascular diseases known to be associated with a low DLCO are pulmonary venoocclusive disease, pulmonary capillary hemangiomatosis, and PAH due to systemic sclerosis (31) (32) (33) (34) .
The latter condition is frequently associated with veno-occlusive changes (33, 35) . Hence, in the absence of parenchymal lung disease, a low DLCO is seen mainly in pulmonary vascular diseases characterized by significant capillary and post-capillary involvement.
Over the past years, additional patient populations have been reported that were characterized by severe PH, a low DLCO, and an exceptionally high mortality.
Trip et al. (15) described a cohort of 166 patients with IPAH, of whom 48 (29%) had a DLCO <45% . Compared with the DLCO $45% group, these patients were older (67 vs. 46 years) and had a more frequent smoking history (58% vs. 30%). As in our study, there were no major differences in pulmonary function and hemodynamics between both groups, but the survival was much lower in the DLCO <45% group (3-year survival 38% vs. 80%). Similar observations were made in patients with lung disease and PH (16, 17) .
It is conceivable that the combination of severe PH and a low DLCO indicates the presence of a unique small-vessel pulmonary vasculopathy that affects post-capillary venules and pulmonary capillaries (15, 29, (36) (37) (38) . Smoking appears to be a major risk factor, which is of particular interest as smoking in various animal models was associated with a small vessel pulmonary vasculopathy that preceded the development of emphysema (39, 40) . However, our Tables 1 and 3 .
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